Market
Story
Lenacapavir Named 'Discovery of the Year' by Science for 100% Efficacy in 2024 HIV Clinical Trial
Dec 13, 2024, 11:51 AM
A new injectable medication, lenacapavir, has been recognized as the 'discovery of the year' by the journal Science for its ability to prevent HIV infection. The medication demonstrated 100% efficacy in a clinical trial involving women in Africa. Global leaders are rallying behind this breakthrough, emphasizing its potential to eliminate HIV worldwide. The recognition of lenacapavir highlights significant advancements in the fight against the virus, marking a pivotal moment in medical research and public health efforts.
View original story
Similar markets
Clinics • 25%
Hospitals • 25%
Community health programs • 25%
Pharmacies • 25%
North America • 25%
Asia • 25%
Africa • 25%
Europe • 25%
Not approved in USA or EU • 25%
Approved in USA only • 25%
Approved in both USA and EU • 25%
Approved in EU only • 25%
Gilead Sciences • 25%
Other • 25%
Global Fund • 25%
PEPFAR • 25%
Asia • 25%
Europe • 25%
North America • 25%
Africa • 25%
South Africa • 25%
Other • 25%
European Union • 25%
United States • 25%